ENGN · NASDAQ · Biotechnology

enGene Therapeutics (ENGN)

Develops non-viral genetic medicines led by a bladder-cancer therapy candidate.

$2.02
vs last close−0.04 (−1.71%)

Something off on this page? Send us feedback.

EPSReportedEstimate

Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Reported−$0.34−$0.48−$0.51−$0.57−$0.73−$0.44−$0.43−$0.47
Estimate−$0.40−$0.37−$0.50−$0.50−$0.57−$0.55−$0.48−$0.43
Surprise+14.1%−30.5%−2.6%−14.5%−28.8%+20.0%+10.4%−10.2%

RevenueReportedEstimate

Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Reported$480.0K
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Oct 2028−$0.13
Jul 2028−$0.13
Apr 2028−$0.34
Jan 2028−$0.31
Oct 2027−$0.26
Jul 2027−$0.27
Apr 2027−$0.31
Jan 2027−$0.31
Dec 2026−$0.46
Sep 2026−$0.43−$0.47−10.2%
Jun 2026−$0.48−$0.43+10.4%
Mar 2026−$0.55−$0.44+20.0%
Dec 2025−$0.57−$0.73−28.8%
Sep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Jan 2024
Jul 2023
Apr 2023
Jan 2023
Oct 2022
Jul 2022
Apr 2022
Dec 2021

The latest year is open to everyone — the 15 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Oct 2028−$0.13$3.0M
Jul 2028−$0.13$3.0M
Apr 2028−$0.34$2.0M
Jan 2028−$0.31$1.0M
Oct 2027−$0.26$1.2M
Jul 2027−$0.27$2.4M
Apr 2027−$0.31$0
Jan 2027−$0.31$0
Dec 28, 2026−$0.46$0
Sep 8, 2026−$0.43−$0.47−10.2%+5.5%
Jun 15, 2026−$0.48−$0.43+10.4%+9.3%
Mar 9, 2026−$0.55−$0.44+20.0%−18.8%
Dec 22, 2025−$0.57−$0.73−28.8%+0.9%
Sep 11, 2025
Jun 12, 2025
Mar 10, 2025
Dec 19, 2024
Sep 10, 2024
Jun 14, 2024
Mar 11, 2024
Jan 29, 2024
Jul 31, 2023
Apr 30, 2023
Jan 31, 2023
Oct 31, 2022
Jul 31, 2022
Apr 30, 2022
Dec 31, 2021

The latest year is open to everyone — the 15 quarters behind it read with an account.